tradmap

LUCY Innovative Eyewear Inc

$0.84 +1.33%

Data as of close

Healthcare · Ophthalmic Goods

Innovative Eyewear Inc (LUCY) is a healthcare company in the Ophthalmic Goods industry, with a market capitalization of $7 million. Shares last traded at $0.84, 61.1% below their 52-week high. Over the past year the stock is down 53.9%. Net profit margin is -225.3%, below the peer median of 1.0%. Revenue grew 62.6% year over year.

Market Cap
$7M
Shares Out
8.6M
EPS (TTM)
-$1.15
P/E (TTM)*
—
P/S Ratio
2.13
P/B Ratio
1.05
Dividend / Share
—
Dividend Yield
—
52-Week High
$2.17
52-Week Low
$0.65
Volume (venue)
920
Avg Vol (3m, venue)
66,044.508

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
+5.49%
1M
-5.50%
3M
+12.52%
6M
-19.24%
YTD
-15.02%
1Y
-53.89%

Daily candles · volume · SMA(20)/SMA(50) · split-adjusted · Databento EQUS.MINI. LUCY split history →

Technicals

RSI (14)
47.60
SMA (50)
$0.90
SMA (200)
$0.98
Price vs SMA50
-6.01%
Price vs SMA200
-13.83%
ATR (14)
$0.04

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$3M
Net Income
-$8M
Gross Margin
22.8%
Operating Margin
—
Net Margin
-225.3%
Return on Equity
-111.4%
Return on Assets
-102.9%
Current Ratio
12.06
Debt / Equity
0.08
Revenue Growth (YoY)
+62.6%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 -$0.26 2026-08-14
Q1 2026 -$0.37 2026-05-14
Q4 2025 (derived) -$0.14 2026-03-25
FY 2025 -$1.90 2026-03-25
Q3 2025 -$0.38 2025-11-13
Q2 2025 -$0.66 2025-08-14

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Ophthalmic Goods peers

LUCY vs 9 industry peers (Ophthalmic Goods), by market cap. Data as of close

P/S vs peers
2.13 / 2.20 med
-3% discount
Net margin vs peers
-225.3% / 1.0% med
below median
1–9 of 9
ALCAlcon Inc$35.9B———+2.97%
COOCooper Companies (The)$11.7B20.442.7513.5%+2.97%
BLCOBausch & Lomb Corp$7.2B—1.32-2.0%+0.18%
WRBYWarby Parker Inc.$2.9B380.793.230.8%-3.07%
EYENational Vision Holdings, Inc.$1.4B26.970.672.5%+3.38%
STAAStaar Surgical Co$1.3B325.823.681.1%+1.61%
RXSTRxsight, Inc.$200M—1.65-38.8%-1.13%
LUCYInnovative Eyewear Inc$7M———+1.33%
LUCYWInnovative Eyewear Inc————+3.93%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.